Business Context and Reporting Period
This Form 6-K filing by GSK plc (GSK) reports a transaction in the company's own shares. The filing date is June 23, 2025, covering a specific share repurchase executed on June 20, 2025. The transaction was conducted through Merrill Lynch International as part of an existing buyback programme under a non-discretionary agreement.
Key Financial Metrics
- Shares Purchased (June 20, 2025): 478,383 ordinary shares.
- Price Range: Lowest price paid was 1,400.50 GBp; highest price paid was 1,444.50 GBp.
- Volume-Weighted Average Price (VWAP): 1,423.28 GBp.
- Cumulative Buyback (Since June 4, 2025): 5,143,219 ordinary shares.
- Treasury Shares Held: 223,277,602 ordinary shares.
- Shares in Issue (Excluding Treasury): 4,092,067,870 ordinary shares.
- Voting Rights in Treasury: 5.46% of total voting rights.
Material Changes
The filing details a reduction in the number of shares in issue and an increase in treasury shares following the June 20 transaction. The percentage of voting rights attributable to treasury shares stands at 5.46% post-transaction. No other material changes to financial position, revenue, or operations are disclosed in this specific filing.
Guidance, Outlook, and Risks
The filing contains no new financial guidance or operational outlook. It includes a standard cautionary statement regarding forward-looking statements, noting that actual results may differ materially due to risks described in GSK's Annual Report on Form 20-F for 2024 and Q1 Results for 2025. The purchase was executed pursuant to a pre-existing non-discretionary agreement, indicating a structured approach to capital return rather than a discretionary market intervention.
Investor Verification Checklist
- Verify the total remaining authorization under the existing buyback programme to assess future repurchase capacity.
- Confirm the impact of the 5.46% treasury share holding on earnings per share (EPS) calculations.
- Review the "Risk Factors" section in the 2024 Form 20-F and 2025 Q1 results as referenced in the cautionary statement.
- Monitor subsequent filings for updates on the cumulative buyback volume against the programme's total limit.